Analysts Remain Positive on BridgeBio Pharma, Inc. (BBIO) After Strong 2025 Results

Company Overview - BridgeBio Pharma, Inc. (NASDAQ:BBIO) focuses on developing therapies for genetic diseases and cancers, with a particular emphasis on precision cancer treatments through its oncology-focused spin-off, BridgeBio Oncology Therapeutics (BBOT) [3]. Financial Performance - For the fourth quarter of 2025, BridgeBio reported preliminary unaudited revenues of $146.0 million, contributing to a total of $362.4 million in product revenue for the full year of 2025 [2]. - The strong revenue figures indicate rapid market adoption of Attruby, which has become a first-choice treatment for newly diagnosed ATTR-CM patients, with over 6,000 unique prescriptions written by the end of 2025 [2]. Analyst Ratings - Truist raised its price target on BridgeBio to $86 from $80 while maintaining a Buy rating, reflecting confidence in the company's future performance [1]. - Analysts remain positive on BridgeBio following the strong results for 2025, indicating a favorable outlook for the company's growth [2].